Home › Funds › Monaco Asset Management SAM › MRVI
Monaco Asset Management SAM position in MRVI
MARAVAI LIFESCIENCES HLDGS I · Health Care
Monaco Asset Management SAM reported holding 647,000 shares of MRVI (MARAVAI LIFESCIENCES HLDGS I) in its Q3 2026 13F filing — a position valued at US$5.0M, representing 0.71% of its reported portfolio and ranking #21 among its reported holdings. Monaco Asset Management SAM has disclosed MRVI holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Monaco Asset Management SAM's MRVI position evolved
Monaco Asset Management SAM first disclosed a stake in MRVI in Q4 2023 at 311,210 shares (US$2.0M). The position peaked in Q2 2026 at 2,231,026 shares, worth US$13.9M. Across 12 filings, Monaco Asset Management SAM increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 647,000 shares valued at US$5.0M — a reduction of -1,584,026 shares quarter over quarter.. Notable position changes include a 288% increase in Q4 2024 (shares fell 59% over the following quarter), a 187% increase in Q1 2025 (shares rose 9% over the following quarter), a 315% increase in Q3 2025 (shares rose 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 311.21K | $2.04M | New |
| Q1 2024 | 158.15K | $1.37M | Reduce |
| Q2 2024 | 200.00K | $1.43M | Add |
| Q3 2024 | 75.00K | $623.25K | Reduce |
| Q4 2024 | 291.36K | $1.59M | Add |
| Q1 2025 | 835.87K | $1.85M | Add |
| Q2 2025 | 880.97K | $2.12M | Add |
| Q3 2025 | 3.66M | $10.49M | Add |
| Q4 2025 | 3.46M | $11.25M | Reduce |
| Q1 2026 | 3.42M | $9.68M | Reduce |
| Q2 2026 | 2.23M | $13.92M | Reduce |
| Q3 2026 | 647.00K | $4.96M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRVI and 13F data
MRVI (MARAVAI LIFESCIENCES HLDGS I) is a Health Care company. 36 other funds we track also report a position in MRVI — the largest reported positions include GTCR LLC (US$125.7M), BRAIDWELL LP (US$54.3M), 12 West Capital Management LP (US$44.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRVI
- GTCR LLC 20.15M sh · $125.74M · Q2 2026
- BRAIDWELL LP 8.70M sh · $54.31M · Q2 2026
- 12 West Capital Management LP 7.06M sh · $44.06M · Q2 2026
- Ophir Asset Management Pty Ltd 4.83M sh · $30.12M · Q2 2026
- GENERAL AMERICAN INVESTORS CO INC 1.72M sh · $13.15M · Q3 2026
- Philosophy Capital Management LLC 1.90M sh · $11.86M · Q2 2026
More on Monaco Asset Management SAM
FAQ
How long has Monaco Asset Management SAM held MRVI?
Monaco Asset Management SAM has disclosed MRVI holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is Monaco Asset Management SAM's current position in MRVI?
As of Q3 2026, Monaco Asset Management SAM holds 647.00K shares of MRVI (MARAVAI LIFESCIENCES HLDGS I), valued at $4.96M, representing 0.71% of its reported portfolio and ranking #21.
Has Monaco Asset Management SAM been buying or selling MRVI?
In the latest 13F filing (Q3 2026), Monaco Asset Management SAM reduced its position in MRVI. The position peaked in Q2 2026 at 2.23M shares.
Which other funds hold MRVI?
Other major institutional holders of MRVI include GTCR LLC, BRAIDWELL LP, 12 West Capital Management LP, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.